Drug Trial Radar · NCT03938636
Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging
Last checked: Nov 20, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Apr 8, 2019
Primary completion
Feb 8, 2021
Study completion Jun 30, 2021
Sponsor
- Lead sponsor
- Navidea BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial will look at scans of the hands and wrists taken from healthy control subjects (HCs) and from subjects with rheumatoid arthritis (RA). Before each scan, subjects will be given an injection of Tc 99m tilmanocept to help the scan identify inflammation in the hand and wrist joints, which can be a part of the RA disease. Data from the scans will be used to calculate a number referred to as tilmanocept uptake value (or TUV) that is a measure of how much Tc 99m tilmanocept has located in the joints. The questions this trial aims to answer are: * How consistent are the scan results (TUVs) when the scans are repeated over time? * What are normal TUVs in healthy people? This will help define abnormally high values in people with RA. * Are TUVs calculated early after a person starts a new drug to treat RA able to predict whether that person will have a good response to the drug later on (after it has had time to take full effect several weeks later)?
Conditions
- Rheumatoid Arthritis
Interventions
Tc 99m tilmanoceptDrug
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arms 1 & 2: Assess Camera-specific Precision of TUVTime frame: Day 0 tilmanocept injection followed by imaging at 60 minutes (60A) and 75 minutes (60B) and at 180 minutes (180A) and 195 minutes (180B).
- Arms 1 and 2: Stability of the Mean/Variance RelationshipTime frame: Day 0 tilmanocept injection followed by imaging at 60 minutes and 180 minutes.
- Arm 3: Correlation of ΔTUVglobal[5w] and Response to TherapyTime frame: Imaging (60 minutes after tilmanocept injection) on Day 0 and at 5 weeks after new therapy initiation; Assessment of CDAI and ACR Response Criteria at 12 and 24 weeks after new therapy initiation.
- Longitudinal (8-day) Variation of TUVTime frame: Imaging (60 minutes after tilmanocept injection) on Day 0 and Day 8
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Imaging Endpoints
Scottsdale, Arizona
Axis Clinical Trials
Los Angeles, California
University of California San Francisco
San Francisco, California
Innovation Medical Research Center
Palmetto Bay, Florida
Physician Research Collaboration
Lincoln, Nebraska
University Hospitals
Cleveland, Ohio
Kettering Medical Center
Kettering, Ohio
Central States Research
Tulsa, Oklahoma
Altoona Center for Clinical Research
Duncansville, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.